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ABSTRACT (max. 200 words) 
INTRODUCTION: Inflammatory bowel disease (IBD) is a chronic inflammatory disorder, 
primarily of, but not restricted to the gut. Extraintestinal manifestations (EIM) are frequently 
observed and involve the joints, eyes, hepatobiliary tract and skin.  
AREAS COVERED: In this review, we discuss classical EIM focusing on epidemiology, genetics 
and pathogenesis, highlighting recent advances in the understanding of EIM. We further 
discuss treatment-induced immunological phenomena, which are increasingly recognized 
and might challenge IBD-treating physicians in the era of biological treatment.  
EXPERT COMMENTARY: 
EIM considerably contribute to morbidity and mortality. Genetic studies have revealed a 
common genetic background between EIM and IBD, and among specific EIM. Identified 
protein interactions have been shown to cluster in shared biological pathways. However – 
despite these recent advances – pathogenesis of EIM is at best partially understood. Several 
pathogenic mechanisms have been proposed such as upregulation of TNF, aberrant 
lymphocyte homing and cross-reactive antigen presentation. It still remains unclear whether 
EIM are a direct result of the inflammatory process in the gut or rather a consequence of a 
shared genetic background leading to dysfunctional immune responses to environmental 
stimuli. Exploration and understanding of EIM genetics, pathophysiology will pave the road 
for better and more efficacious treatment options in the future. 
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1. INTRODUCTION 
Inflammatory bowel disease (IBD) with its two subtypes Crohn`s disease (CD) and ulcerative 
colitis (UC), is defined as a chronic inflammation of the intestine, which arises from a 
complex interplay between a dysfunctional host immune response and environmental 
triggers.1,2 However, it has become apparent that IBD is a systemic disorder, that primarily 
affects the gut, but which is not restricted to the intestinal tract. So-called extraintestinal 
manifestations (EIM) – an umbrella term for IBD-associated manifestations outside of the 
gut – are indeed frequently observed.3,4 EIM considerably contribute to morbidity and 
mortality in IBD patients.5,6 Yet, there is no uniform definition of EIM. Published reviews and 
studies included different sets of EIM. In most analyses, EIM are at least distinguished from 
IBD-associated complications such as osteoporosis, anemia or micronutrient deficiency. 
These complications are a direct consequence of the intestinal inflammation rather than a 
distinct inflammatory process. EIM can be defined as an inflammatory entity caused by the 
same processes that drive inflammation in the gut, but which is located outside of the 
intestine, in a patient with IBD.2 From a more mechanistic perspective, EIM may be classified 
into specific, reactive, associated and treatment-induced.4,7 While specific EIM represent the 
same disease as IBD, but are located outside of the gut (such as metastatic or 
mucocutaneous CD), reactive EIM share pathogenic mechanisms with IBD without exhibiting 
the same histomorphological characteristics.4 For associated EIM, pathogenic link remains 
unclear, but they are more frequently observed in the context of IBD compared to controls. 
Treatment-induced EIM show a temporal association with IBD treatment and disappear 
upon cessation of the culprit treatment regimen.8 Due to the rarity of some EIM, 
determination of their association with IBD is challenging and might be confounded by a 
recall bias resulting in an overestimation of the association between EIM and IBD. 
Furthermore, it still remains unclear whether EIM are a direct result of the inflammatory 
process in the gut or rather a consequence of a shared genetic background leading to 
dysfunctional immune responses to environmental stimuli. In this review, we will discuss 
classical EIM focusing on epidemiology, genetics and pathogenesis, particularly highlighting 
advances in understanding of EIM in recent years. Finally, we will discuss treatment-induced 
immunological phenomena, which are increasingly recognized and might challenge IBD-
treating physicians in the era of biological treatment. 
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2. CLASSIFICATION OF EIM 
A classical definition of EIM includes the four following organ systems: 1) musculoskeletal 
system (arthritis, spondylarthropathy); 2) eyes (episcleritis, uveitis), 3) skin (pyoderma 
gangrenosum, erythema nodosum, stomatitis); and 4) hepatobiliary system (primary 
sclerosing cholangitis (PSC)).2,3 These EIM may or may not parallel intestinal disease activity; 
Erythema nodosum, episcleritis and type 1 arthritis are typically associated with intestinal 
disease, while spondylarthropathy and type 2 arthritis do not correlate with intestinal 
inflammation. For some EIM such as pyoderma gangrenosum or uveitis correlation with 
intestinal disease activity is less clear.9-12 For details see Figure 1. Recent studies revealed 
that EIM mostly manifest after the diagnosis of IBD is established, within a median of 92 
months. However, in a non-negligible proportion of patients (25.8%) EIM occur before IBD. 
In these patients median time from EIM to IBD is 5 months, although in some patients EIM 
might be found more than two years before IBD diagnosis.13 Similar findings are reported in 
the pediatric IBD population.14 In the following, we will describe classical EIM and their 
clinical presentation in more detail. 
Musculoskeletal 
Musculoskeletal EIM include three disease entities: 1) type 1 peripheral arthritis, 2) type 2 
peripheral arthritis, and 3) axial spondylarthropathy. Peripheral arthritis shows a non-
destructive course.2,8 It usually is seronegative; neither rheumatic factor nor anti-nuclear 
antibodies can be detected.9 Peripheral arthritis is more frequently observed with colonic 
and/or perianal involvement and is further associated with erythema nodosum, stomatitis 
and pyoderma gangrenosum.9,15 The following classification can be applied: type 1 vs. type 
2. Type 1 is a pauciarticular manifestation with involvement of less than 5, mostly large 
joints such as knee or ankle. Disease course is acute, often asymmetrical and migratory.2 It 
usually parallels intestinal disease activity.16 In contrast, type 2 arthritis affects smaller joints 
(most often MCP), shows involvement of 5 or more joints and runs independently of 
intestinal disease activity.2 While type 1 arthritis is usually self-limiting, type 2 disease can 
persist up to several years.16 Given the absence of serum markers and missing destruction 
on plain films, diagnosis is typically made based on clinical examination.17 Arthritis should be 
distinguished from arthralgia, which is simple joint pain without any evidence of 
inflammation.8 The latter is frequently observed and non-specific. Axial spondylarthropathy 
affects the spine and/or the sacroileal joint. It can be subclassified into ankylosing spondylitis 
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and sacroiliitis.2 Ankylosing spondylitis presents similarly to the non-IBD associated form: 
Patients, particularly males, complain of worsening back pain, which starts at relatively 
young age. Further symptoms are morning stiffness and aggravating pain during rest. On 
clinical examination, spine mobility is considerably decreased. In early stages, plain films 
might be normal, while in later stages, typical findings such as syndesmophytes, vertebral 
body squaring and ankylosis can be detected.2 In contrast to ankylosing spondylitis, isolated 
sacroiliitis is more frequently seen.18-21 It ususally does not show progression to ankylosing 
spondylitis. However, this risk is increased with bilateral joint involvement.22 The diagnosis 
of spondylarthropathies can be made based on symptoms, clinical examination and 
radiographic findings.8 MRI is more sensitive than plain films, particularly in early disease 
stages.23,24 Given an association with HLA-B27 (see genetics),25 testing for this HLA genotype 
might be helpful in case of diagnostic uncertainties.  
Skin 
Skin manifestations of IBD have been described in more detail very lately.4 Briefly, the typical 
cutaneous EIM include erythema nodosum, pyoderma gangrenosum, and stomatitis.4,8 The 
latter has to be distinguished from CD of the oral cavity. Erythema nodosum is clinically 
defined as symmetric, raised, tender, red-violet subcutaneous nodules.2 Their diameter vary 
from 1 to 5cm. Erythema nodosum typically localizes on the extensor surfaces of the lower 
extremities, the anterior tibia is its most frequent localization.26 While erythema nodosum is 
known to parallel intestinal disease activity, severity does not correlate with degree of 
intestinal inflammation.27,28 Risk factors are colonic involvement and occurrence of other 
EIM, particularly pyoderma gangrenosum.29 Pyoderma gangrenosum is the most severe and 
debilitating cutaneous manifestation in IBD.4 It is characterized by a fast development from a 
painful erythematous papule or pustule to a dermal necrosis and finally deep ulcerations 
with purulent, but sterile discharge.8 Pyoderma gangrenosum commonly localizes on the 
shin or in the peristomal area.2 It might be accompanied by systemic symptoms. Diagnosis 
can be made based on clinical examination. Biopsies might be helpful to rule out infection, 
but any manipulation may worsen the disease.30 This phenomenon is known as pathergy 
effect.31 Mucocutaneous EIM in the oral cavity include (aphthous) stomatitis and 
periodontitis. Typical findings are painful ulcers of the labial and buccal mucosa.30 
Peristomatitis vegetans is its most severe form.4,30 Periodontitis presents as gingival swelling 
and redness.32 These oral manifestations usually parallel intestinal inflammation. 
Extraintestinal manifestations in IBD                                                                                      Page 5 
Ocular 
Episcleritis and uveitis are the most common ocular manifestations in IBD.8 While episcleritis 
describes a mild disease, uveitis is usually more severe and may result in visual impairment. 
Episcleritis is defined as an inflammation of the episclera, which presents with a painless 
injection of the sclera and conjunctiva.2,33 Burning and itching may be present. In contrast, 
uveitis manifests with considerable pain, photophobia, blurred and eventually decreased 
vision. Uveitis can be categorized into the following four subtypes depending on the 
localization of inflammation: 1) anterior (=iritis), 2) intermediate (=vitritis), 3) posterior 
(=choroiditis), and 4) panuveitis.8 While episcleritis paralles intestinal disease, uveitis does 
not.34 Urgent ophthalmologic examination (with a slit-lamp) is warranted in case uveitis is 
suspected.8,33  
Hepatobiliary 
PSC is a cholestatic liver disease, characterized by inflammation and fibrosis of the biliary 
tract.35 It considerably contributes to morbidity and mortality, particularly in UC patients.8,36 
Cancer risk – both for colorectal cancer and cholangiocellular carcinoma – is increased.37-40 
Risk factors for PSC are: 1) extensive colitis, 2) backwash ileitis, and 3) male sex.11,41 PSC is 
diagnosed based on a cholestatic pattern of liver enzymes and biliary strictures, segmental 
dilations on MRCP or ERCP.8,42-44 Other hepatobiliary manifestations of IBD include fatty 
liver, granulomatous hepatitis, autoimmune liver disease, and pancreatitis.45  
 
3. EPIDEMIOLOGY 
Overall, 6-47% of IBD patients experience at least one EIM.18,26,46-51 Arthritis is the most 
common EIM, followed by stomatitis, uveitis, erythema nodosum and axial 
spondylarthropathy.3 In a considerable proportion of patients (36.6%), more than one EIM 
are observed. A subset of patients (2.7%) may actually present with up to five EIM. Several 
factors increase the likelihood of developing EIM: 1) EIM are significantly more frequent in 
CD compared to UC patients;3,14,52 2) EIM are more frequent with longer IBD duration;51 3) In 
CD patients, female sex, age, and disease activity have been identified as independent 
predictors for the presence of EIM;3 and 4) In UC, extensive colitis was significantly 
associated with the presence of EIM.6 EIM typically manifest after the diagnosis of IBD has 
been established with a median time from IBD to first EIM of more than 7 years.13 
Nonetheless – at least in a subset of patients (25.8%) – EIM can also occur before IBD 
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diagnosis. This was particularly seen for uveitis (52.2%) and axial spondylarthropathy 
(39.1%).13 Other EIM such as pyoderma gangrenosum and erythema nodosum rarely 
manifest before IBD diagnosis. In contrast to the increasing knowledge about EIM in adult 
IBD, much less is known about EIM in the pediatric population. At IBD onset, EIM appear to 
be more frequent in children compared to adults.14,53 However, frequency overall seems to 
be lower than in the adult population, which might be attributed to a shorter IBD 
duration.14,54,55 Otherwise, EIM appear to be fairly similar in children and adult: Our group 
has recently shown that EIM are more frequent in CD than UC, and that the most frequent 
EIM is arthritis followed by aphthous stomatitis and uveitis.14 There are only minor 
differences such as higher rates of arthritis and lower rates of spondylarthropathies in 
children compared to adults.14 In the following, we discuss the epidemiology of specific EIM 
in more detail focusing on data from adult cohorts. In general, prevalence of EIM has been 
reported with a large variation. This might be attributed to different definitions of EIM, 
different study designs (prospective vs. retrospective) and considerable differences 
regarding EIM diagnostics.  
Musculoskeletal 
Peripheral arthritis has been reported with a prevalence ranging from 5 to 20%. It appears to 
be more common in CD (10-20%) than UC (5-10%) and is more frequently observed in 
females.8,16 Colonic involvement has been identified as a risk factor for the presence of 
peripheral arthritis.2,9 Spondylarthropathies occur in up to 25%, but most studies reported 
lower frequencies.6,26,49-51 Subclinical disease – diagnosed based on radiographic findings – 
appears to be more frequent.2,18 Males are more commonly affected.2 
Skin 
In contrast to most EIM, pyoderma gangrenosum is more common in UC than CD.56-59 
Females are more often affected.60 The prevalence of pyoderma gangrenosum is however 
rather low; it ranges from 0.4 to 2%.3,18,58,59 Erythema nodosum is more frequently seen than 
PG, its prevalence has been reported with up to 15%.2,26 It is considered the most frequent 
cutaneous manifestation of IBD.4 Frequency appears to be higher in CD than UC, and also in 
females compared to males. Stomatitis is also a common cutaneous IBD manifestation.3,50 In 
the Swiss IBD cohort, its prevalence was 7.4% (CD 9.8 vs UC 3.5%).3 Exact numbers for 
peristomatitis vegetans, a particularly severe form of stomatitis, are currently unknown. 
Prevalence of periodontitis in IBD has not been systematically assessed. However, a case-
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control study showed its association with IBD, particularly perianal disease.32 Periodontitis 
per se, regardless of IBD, is however relatively common (up to 50%).61  
Ocular 
4-12% of IBD patients have ocular manifestations.62 Ocular EIM are more frequent in CD 
than UC.3,6,26,49,51 In some cohorts, prevalence is reported with up to 29%.8,62  Most patients 
present with episcleritis, while uveitis is less common with a prevalence of 0.5-3%.12 The 
Swiss IBD cohort – however – reported higher uveitis rates (5.3%).3 Very severe forms, such 
as scleritis, intermediate or posterior uveitis are extremely rare.63  
Hepatobiliary 
PSC is the most common IBD-specific hepatobiliary manifestation.44 Prevalence has been 
reported with 4-5%.64,65 However, geographic variation in PSC prevalence has been 
observed.66 In the nation-wide Swiss IBD cohort, PSC was detected in 1.8% of all patients, 
and in 3.5% of patients with UC, which are at increased risk for disease development. In 
contrast to PSC, non-specific hepatobiliary manifestations are more frequently encountered: 
It is estimated that up to 30% of IBD patients present with abnormal liver function tests or 
are affected by hepatobiliary manifestations during the course of their disease.67 
 
4. GENETICS 
EIM are frequently associated with each other, and the presence of one EIM increases the 
risk for further EIM.3,13,68 More than a third of patients presents with at least two EIM, while 
10% report three or more EIM.13 One explanation for these findings are that EIM share 
common genetic pathways. NOD2, which is a well-known risk factor for CD, has been 
identified as risk factor for sacroileitis and uveitis, two common EIM in CD.69,70 Based on 
association studies, epidemiological data and genome-wide association studies, it has 
become increasingly apparent that genetics contribute to the development of EIM. An 
extensive summary of possible genetic factors has been recently published in an ECCO 
workshop paper.71  
Epidemiological studies 
The impact of genetic factors on the development of EIM has first been suggested by 
findings from association studies showing concordance of EIM in 70% of parent-child pairs 
and 84% of sibling pairs.72 Furthermore, high rates of positive family history of IBD were 
observed in patients presenting with EIM. Indeed, positive family history is an independent 
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predictive factor for the occurrence of EIM in CD patients.3 Population-based studies further 
revealed different prevalence rates for EIM in the West (17-63%) compared to the East (5-
40%).66,73 Such difference is particularly seen for PSC, which is less frequently reported in 
Asia than in the Western hemisphere.66 The likelihood of diagnosing an underlying IBD 
associated with PSC, is considerably lower in the East compared to the West.74-78 Besides 
geographic differences in EIM and PSC prevalence, frequency of EIM appears to be different 
among specific ethnic groups: Joint complications are more frequently seen in African-
Americans and Asians, while EIM per se appear to be more common among Indians 
compared to Malays and Chinese.79,80 These data indicate: 1) a possible common genetic 
background in EIM patients; and 2) a contribution of genetic factors to the development of 
EIM.  
HLA genotypes 
Human leukocyte antigens are recognition molecules that initiate immune responses. 
Polymorphism in HLA genotype can increase the susceptibility for the development of auto-
inflammation.81 Indeed, genetic variations in HLA have been shown to increase the risk for 
specific EIM. One of the best-known genetic risk factors for occurrence of EIM is HLA-B27. 
HLA-B27 has been associated with joint, skin and ophthalmologic manifestations, particularly 
axial spondylarthropathy and type 1 arthritis. This association is rather specific: Patients with 
axial spondylitis are positive for HLA-B27 in 50-90%, while for patients with sacroiliitis 
without spondylarthropathy HLA-B27 positivity is only seen in 7-15%.8,82 However – despite 
this association with EIM – HLA-B27 does not increase the risk for IBD.46 Further identified 
HLA genotypes associated with EIM are: 1) HLA-B8/DR3 for PSC, 2) HLA-B35 for type 1 
arthritis, 3) HLA-B44 for type 2 arthritis, 4) HLA-B58 for skin, joint and ophthalmologic 
manifestations, and 5) HLA-DRB1*0103 for skin, joint and ophthalmologic manifestations, 
particularly type 1 arthritis.12,83-85 Several HLA increase the risk of EIM per se, irrespective of 
a specific EIM subtype: Increased risk of EIM has been observed among CD patients with 
HLA-A2, HLA-DR1 and HLA-DQw5, while in UC such increase was associated with HLA-DR103, 
HLA-B58, and HLA-B27.12,84,86 Taken together, many EIM seem to share a common genetic 
background in terms of HLA genotypes, although at least some EIM represent 
immunogenetically distinct entities (such as type 1 vs. type 2 arthritis). It has yet to be 
determined if HLA polymorphisms indeed increase EIM rates in IBD or rather predispose to 
IBD subtypes, which are associated with higher EIM frequency.  
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Genome-wide association studies 
Genome-wide association studies (GWAS) are a powerful tool to investigate similarities 
between diseases in terms of a shared genetic background. Several known IBD risk loci have 
been linked to EIM highlighting a considerable genetic overlap.87-92 However, at least for 
PSC, no such overlap was seen indicating a rather immunogenetically distinct background.8,93 
IBD risk loci, which are associated with EIM, are shown in Table 1. 
Implications of genetic studies in EIM and IBD 
Protein interactions identified by genetic studies may cluster in shared biological 
pathways.87 So, genetic studies can help to elucidate EIM pathogenesis and to identify novel 
mechanisms such as the druggable JAK-STAT pathway. Investigating the function of newly 
discovered genes involved in EIM pathogenesis may help to unravel novel therapeutic 
targets. However, such analyses do not answer the question, whether EIM are a true 
consequence of IBD, or if EIM and IBD are different manifestations of a genetically 
determined, dysfunctional host immune response to environmental stimuli. 
 
5. PATHOGENESIS 
The pathogenesis of EIM is at best partially understood. A common pathogenic pathway is 
suspected since one EIM increases the susceptibility for another EIM and because EIM tend 
to appear simultaneously.13 From a high level perspective, EIM may arise from expansion of 
intestinal disease activity beyond the gut mediated through various mechanisms such as 
aberrant lymphocyte homing or cross-reactivity. EIM may also simply develop from a 
proinflammatory state with upregulation of specific cyto- and chemokines resulting in a 
dysbalance of immunocomponents. Most probably, several specific pathomechanisms are 
involved, which are not mutually exclusive. In the following, we discuss pathogenic factors, 
which have been proposed to contribute to the development and presence of EIM, in more 
detail. For an overview see Table 2.  
TNF-pathway 
In IBD, antigen-presentation to antigen-presenting cells (APC) and the interaction of APC 
with T helper cells lead to activation of macrophages. Activated macrophages then produce 
a mix of broadly active inflammatory cytokines, including tumor necrosis factor (TNF).94 TNF 
exhibits its action through binding to death receptors of the TNF receptor family.95 These 
receptors can trigger caspase activity and apoptosis in response to ligand binding.96 TNF can 
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also further enhance inflammatory response through the NFkB pathway, which leads to 
upregulation of various interleukins, cyto- and chemokines.94 Inhibition of TNF signaling has 
been a successful strategy in IBD treatment. It has further been a strategy in other chronic 
inflammatory diseases such as psoriasis and rheumatoid arthritis. Recent studies have 
suggested efficacy of anti-TNF in the management of various EIM.97,98 Anti-TNF appear to be 
particularly efficacious in the treatment of cutaneous EIM and arthritis, although most data 
evolve from non-controlled open-label trials or non-interventional (retrospective) studies. 
Best evidence is available for pyoderma gangrenosum, where a randomized-controlled trial 
revealed response rates of 46% and complete remission of 21%.99 These data have indicated 
a common TNF-shared pathogenic link between IBD and EIM, and among specific EIM. Our 
group has identified upregulation of the TNF-NFkB pathway in human biopsy specimens 
from erythema nodosum and pyoderma gangrenosum.100 Interestingly, this upregulation 
was higher than that seen for psoriasis. However, despite this growing evidence for TNF 
involvement in the pathogenesis of EIM, it remains unclear if this represents an expansion of 
intestinal disease activity to extraintestinal sites or if it is rather the consequence of a 
generally pro-inflammatory state (dysbalance of cytokines) in genetically susceptible 
patients. The latter might be supported by the fact that TNF is not only increased in 
intestinal lesions, but also detected in the serum of IBD patients.   
Cross-reactive antigens and gut-synovial axis 
Cross-reactivity of antigens (molecular mimicry) is a known mechanism of autoimmune 
diseases. When foreign antigens share sequences or structural similarities with self-antigens, 
autoimmune response can be triggered.101 In the context of IBD and EIM, microbiota 
antigens are of particular importance. It has been shown that germ free HLA-B27 transgenic 
mice are not able to develop joint inflammation.102 This indicates that exposure to bacterial 
antigen is a sine-qua-non for the development of spondylarthropathy, even in the context of 
a genetic predisposition.103 This importance of bacterial exposure in the gut in the 
pathogenesis of EIM is referred to as the so-called gut-synovia axis. Th1/Th17 lymphocytes 
are primed in the gut, which then home to synovial tissue triggering an inflammatory 
response.104 It has yet to be determined if microbiota can be effectively targeted to treat 
EIM. 
Aberrant lymphocyte recruitment/homing 
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Gut-specific lymphocytes might invade extraintestinal sites if they express gut-specific 
chemokine or integrin receptors.105,106 This has been shown for PSC, in particular.106 
However, beyond PSC, there is not much evidence for such ectopic expression of receptors 
leading to aberrant lymphocyte homing. Our group has recently analyzed 31 biopsy samples 
from erythema nodosum and pyoderma gangrenosum showing no evidence for expression 
of gut-specific MAdCAM in the skin.100 However, lymphocytes might co-express gut-specific 
and skin-specific homing ligands, which enable tropism to extraintestinal sites.107 Other 
mechanisms are the use of non-specific ligands and receptors for lymphocyte-endothelial 
cell interaction such as VAP-1, which is expressed in the gut, eyes and joints.107,108 Despite 
absence of MAdCAM expression in non-intestinal tissue, recent studies suggested efficacy of 
vedolizumab in EIM management; complete remission of inflammatory arthralgia/arthritis 
and cutaneous EIM was achieved in 44.7 and 75%, respectively.109 Improvement was mainly 
associated with quiescent IBD. Thus, it remains elusive whether this is a direct effect of 
vedolizumab on EIM or whether this rather happens indirectly through controlling intestinal 
disease activity.  
Taken together, both specific and non-specific lymphocyte-endothelial cell interaction may 
induce lymphocyte homing to different organs and promote inflammation at extraintestinal 
sites.  
Autoimmune mechanism 
Autoimmune mechanisms appear to be involved at least in some EIM. Circulating 
perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA), which can be found in serum 
from CD patients, have been linked to PSC, EN and uveitis.83 In addition, vasculitis with 
deposition of complement factor C3 in the endothelial basement membrane is a frequent 
finding in biopsies from patients with aphthous stomatitis.110 However, it has yet to be 
determined if these antibodies are pathologically relevant or rather an epiphenomenon.  
Environmental factors 
Although auto-inflammatory processes arise from an exposure to environmental triggers in 
genetically susceptible patients, not much is known about external factors in the 
pathogenesis of EIM. Relative rarity of events is the main limitation to identify pathogenic 
environmental factors. In addition, results may be confounded by a recall bias. Nonetheless, 
in a cross-sectional analysis of three IBD cohort studies, smoking has been identified as an 
independent risk factor for EIM in both CD and UC.111 Of note, this association between 
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smoking and EIM was dose-dependent.111 Furthermore, smoking cessation was associated 
with a reduction of EIM prevalence.111 Both findings make the results more reliable. Yet, 
prospective trials are missing showing positive effects of smoking cessation on specific EIM. 
Nonetheless, based on the current data, smoking cessation should be recommended in all 
patients.  
Other proposed mechanisms 
Other pathogenic mechanisms have been proposed, particularly for cutaneous 
manifestations,s such as abnormal neutrophil function and impaired cellular immunity in 
pyoderma gangrenosum, type III hypersensitivity reaction in Sweet`s syndrome, which is a 
systemic form of neutrophil dermatosis, and type IV hypersensitivity in erythema 
nodosum.8,30,112,113  
 
6. TREATMENT INDUCED IMMUNOLOGICAL LESIONS  
Treatment-induced inflammatory manifestations have long been an under-reported 
problem, but they have received growing attention in recent years.114,115 With the wide use 
of biologics, anti-TNF in particular, reports on such manifestations have been rapidly 
increasing. While in 2009, a total of only 127 patients presenting with anti-TNF induced 
manifestations have been reported, the prevalence is nowadays considered to be up to 22% 
in some cohorts.8,116 The inclusion of treatment-induced lesions as EIM is controversial; 
some reviews rather consider them as treatment-induced side effects. However, given their 
likely immunological background and since the first ECCO guidelines on EIM clearly consider 
them amongst EIM, we herein discuss treatment-induced inflammatory manifestations in 
more detail. Diagnosis of treatment-induced lesions is usually clinical-based and includes: 1) 
assessment of time-point of appearance (after initiation of treatment); 2) disease course 
after discontinuation of treatment (they usually disappear and resolve completely); and 3) 
possible re-challenge with the same agent. The most frequent treatment-induced 
inflammatory manifestations are discussed in the following section with a focus on anti-TNF 
and vedolizumab. 
Anti-TNF 
Anti-TNF induced skin lesions are the best-studied treatment-induced manifestation in IBD. 
These lesions present as either eczematiform or psoriasiform skin eruptions.4 Eczematiform 
eruptions are characterized by xerosis and pruriginous plaques with erythematous or 
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squamous vesicles, while a psoriasiform presentation exhibits scaly erythematous plaques, 
pustulosis and eventually nail involvement.8,117 The frequency of anti-TNF induced skin 
lesions is reported with 5-10%, but higher rates were detected in some cohorts.8,115,118 These 
lesions usually respond well to local treatment (eg steroids) and anti-TNF agents can often 
be continued.4 However, in up to 34% cessation of treatment is necessary.118 A switch to 
another anti-TNF agent is not recommended given a class-effect. Ustekinumab, an IL12/23 
antibody, has been successfully used as an alternative treatment option.119 Anti-TNF induced 
joint manifestations – inflammatory arthralgia or arthritis – are considerably less frequent 
than skin lesions.115,120 These manifestations are frequently associated with positive anti-
nuclear antibodies (ANA) and anti-ds DNA antibodies.121 Only few cases of ocular 
manifestations (uveitis, scleritis) have been described.122,123 A special anti-TNF induced 
manifestation is the lupus-like syndrome, which presents with fever, rash and arthralgia.115 
ANA and anti-dsDNA antibodies can be detected. Withdrawal of the offending drug results in 
complete resolution of the syndrome. However, symptoms might recur with a second anti-
TNF. Switch to certolizumab might be favorable given lower frequency of ANA positivity.115 
In contrast to the rarity of lupus-like syndrome, ANA and anti-ds DNA antibodies can be 
found in up to 46-57% of asymptomatic, anti-TNF treated patients.124 The pathogenesis of 
anti-TNF induced inflammatory manifestations remains incompletely understood. Different 
mechanisms have been proposed: 1) increased IFNalpha production, 2) cytokine imbalance, 
3) compensatory T-cell expansion, and 4) autoimmunity.4 115 TNF is known to inhibit 
maturation of plasmocytoid dendritic cells (PDC) from hematopoietic progenitor cells.125 PDC 
can produce IFNalpha, an important mediator in psoriasis. Anti-TNF agents can therefore de-
inhibit this maturation, which leads to an increase of PDCs and finally IFNalpha 
production.126 Anti-TNF treatment might also result in a compensatory expansion of 
Th1/Th17 cells in areas other than the gut, which triggers inflammation in extraintestinal 
sites such as the skin.127,128 Anti-TNF mediated reduction in clearance of 
immunocomponents can further lead to a cytokine dysbalance, while increased exposure of 
cellular nuclear components may result in antibody formation (such as ANA and anti-dsDNA 
in lupus-like syndrome). 114,115 
Vedolizumab 
Extraintestinal effects of vedolizumab, an anti-integrin a4b7 antibody, has been questioned 
given the gut-specific expression of MAdCAM1, which acts as receptor for a4b7.100 However, 
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as previously stated, there is growing evidence that vedolizumab can positively affect EIM 
disease course. A comprehensive analysis of 294 vedolizumab-treated IBD patients revealed 
complete resolution of joint manifestations in 44.7%, which was particularly attributed to 
clinical remission of IBD.109 In a case series, vedolizumab had positive effects on pyoderma 
gangrenosum, uveitis, erythema nodosum, arthropathy and spondylarthropathy.129 
However, compared to anti-TNF, prevention of EIM appears to be less effective, most 
probably due to a more gut-specific mode of action.130 Nonetheless, despite positive effects, 
vedolizumab has also been associated with treatment-induced inflammatory manifestations 
such as arthralgia/arthritis (13.8%) and skin-lesions (4.8%).109 Pathomechanisms of these 
paradoxical manifestations remain unclear. They might be a consequence of aberrant 
lymphocyte homing or compensatory T cell expansion at extraintestinal sites.  
Others 
Not much is known about the potential of other biologics to cause treatment-induced 
inflammatory manifestations. Ustekinumab has been associated with development of 
pustular psoriatic skin lesions despite its positive effect on anti-TNF induced skin 
manifestations. Nothing is known with regards to JAK inhibitors, but non-specific rash has 
been described as possible side-effect.131  
 
7. CONCLUSIONS 
Extraintestinal manifestations in IBD are frequent and considerably affect morbidity and 
mortality. A strong genetic background is increasingly recognized. Pathogenesis – however – 
remains at least partially elusive, and most probably several not mutually exclusive 
mechanisms are involved such as molecular mimicry, aberrant lymphocyte homing and 
cytokine imbalance with upregulation of proinflammatory cytokines such as TNF. Treatment-
induced immunological phenomena are observed with an increasing frequency. As we learn, 
these treatment-induced manifestations are not restricted to anti-TNF therapy. Elucidation 
of genetic and pathogenic mechanisms of both EIM and treatment-induced manifestations 
will eventually help to identify novel therapeutic targets in the future. 
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EXPERT COMMENTARY 
Extraintestinal manifestations of CD and UC represent a challenge in clinical IBD practice. 
Extraintestinal does not only indicate outside of gut, it also means outside of the scope of 
many gastroenterologists. However, consideration and diagnosis of EIM is key for various 
reasons: 1) EIM considerably affect morbidity and mortality; 2) EIM can indicate ongoing 
intestinal disease activity despite absence of symptoms; and 3) EIM can present before a 
diagnosis of EIM is established. Therefore, presence of EIM should prompt physicians to 
screen for IBD in non-IBD patients and to assess intestinal disease activity in IBD patients. 
Although there has long been a consensus that IBD is not restricted to the intestinal tract 
and rather represents a systemic inflammatory disease, it took a long time until the first 
guidelines on EIM have been published. This might be attributable to the fact that EIM fall 
into a nebulous space between gastroenterology and non-gastroenterology subspecialities 
such as rheumatology, ophthalmology and dermatology. It has now become apparent that – 
in order to provide the best care for IBD patients – a multidisciplinary approach is needed. 
Such close interaction and collaboration between specialists will be key to success for both 
clinical care and research. In the era of biological treatment, the gastroenterologist is more 
than ever rather a team player than an individualist. 
Clinical, translational and basic research are currently limited by the lack of a clear, uniform 
and generally accepted definition of EIM. Particularly the inclusion of both non-inflammatory 
arthralgia and inflammatory arthropathy result in inaccuracy and make it more difficult to 
draw clear conclusions from some observational studies. Further limiting factors are the 
relative rarity of some EIM, which results in low number of patients in cross-sectional 
analyses, and the retrospective study design of most published analyses. However, the 
release of the first ECCO consensus guidelines certainly boosted the field and and several 
important advances have been achieved in recent years. It has become apparently clear that 
EIM have a strong genetic background and specific pathomechanisms have been identified 
contributing to EIM development. Further mechanistic studies will help to unravel EIM 
pathogenesis, which will ultimately lead to the identification of novel therapeutic targets. 
Findings from genetic studies facilitate the identification of such novel, potentially druggable 
pathways. From our perspective, the following research tasks are key and will be likely 
addressed in the near future: 
- Finding consensus regarding a uniform and widely accepted definition of EIM 
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- Exploration of EIM pathogenesis 
- Investigation of frequency and pathogenesis of non-anti-TNF mediated treatment-
induced manifestations  
Ultimately, one of the burning questions in EIM research is: Are EIM a direct consequence of 
the intestinal disease? Or are IBD and EIM two manifestations of a genetic susceptibility with 
an abnormal immune response to external stimuli? 
Addressing these tasks and questions may pave the road for better and more efficacious 
treatment options in the future. 
 
FIVE-YEAR VIEW 
Given the relative rarity of some EIM, particularly in a cross-sectional setting, multicenter 
approaches to increase case load and access to patient samples will be key for successful 
EIM research in the future. Single cell RNAseq analyses are a novel and interesting tool to 
study EIM pathogenesis. Single cell sequencing can characterize cell subpopulations in more 
detail than the traditional FACS analyses. Applying this technique to T cells from intestinal 
and extraintestinal sites will eventually address the question whether or not inflammation at 
extraintestinal sites represents the same disease as seen in the intestine. Decreasing costs 
and better accessibility will facilitate its use in the future. Introduction and increasing use of 
novel biological agents such as JAK inhibitors, anti-integrins and anti-IL12/23 will likely show 
if treatment-induced lesions are unique to anti-TNF or if they can occur with any drug 
interfering with IBD pathogenesis.  
 
KEY ISSUES 
- EIM are frequent and considerably affect morbidity and mortality in IBD patients. 
- EIM have a strong genetic background. 
- Pathogenesis of EIM is at best partially understood. Several not mutually exclusive 
mechanisms are involved, such as cross-reactivity, cytokine imbalance and aberrant 
lymphocyte homing. 
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LEGENDS 
Figure 1: Classification of EIM and association of specific EIM with IBD. Green dots indicate 
association with intestinal disease activity, while red dots indicate that EIM do not parallel 
intestinal disease activity. Green and red dots together indicate that this specific EIM may or 
may not parallel intestinal disease activity. 
Table 1: Genetic risk factors for development of extraintestinal manifestations. 
Table 2: Proposed pathogenic mechanisms for extraintestinal manifestations. 
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TABLES 
Table 1 
Analyses Genetic risk factors 
HLA genotypes HLA-B27: joint, skin and opthalmologic manifestations, particularly 
axial spondylarthropathy 
HLA-B8/DR3: PSC 
HLA-B35: type 1 arthritis 
HLA-B44: type 2 arthritis 
HLA-B58: joint, skin and opthalmologic manifestations 
HLA-DRB1*0103: joint, skin and opthalmologic manifestations 
HLA-A2: EIM in general 
HLA-DR1: EIM in general 
HLA-DQw5: EIM in general 
GWAS for axial 
spondylarthropathy 
and IBD 
IL23R 
IL12B 
STAT3 
PTERG4 
CARD9 
IL1R2 
ORMDL3 
GWAS for psoriasis 
and IBD 
IL12B 
IL23R 
JAK2 
STAT3 
GWAS for EN and 
IBD 
CLCA2 
LY75 
2q24.1 
NOD2 Risk factor for ileal CD, sacroileitis, and uveitis 
Table 1: Genetic risk factors for development of extraintestinal manifestations. EIM, 
extraintestinal manifestatinos; EN, erythema nodosum; GWAS, genome wide association 
study; HLA, human leukocyte antigen; IBD, inflammatory bowel disease 
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Table 2 
Pathogenic mechanisms 
TNF pathway Upregulation of TNF at extraintestinal sites in the context of EIM 
such as EN or PG. 
Cross-reactivity Microbiota antigens sharing similarities with self-antigens, gut-
synovia axis 
Autoimmunity Circulating antibodies (p-ANCA), vasculitis with C3 deposition 
Aberrant 
lymphocyte homing 
Lymphocyte homing to extraintestinal sites due to ectopic 
expression of gut-specific receptors (MAdCAM1), co-expression of 
gut- and extraintestinal-site-specific ligands (a4b7 integrin and CLA), 
and expression of non-site-specific ligands (VAP-1) 
Others Abnormal neutrophil function, impaired cellular immunity, Type III 
hypersensitivity reaction, Type IV hypersensitivity 
Table 2: Proposed pathogenic mechanisms for extraintestinal manifestations. EN, erythema 
nodosum; IBD, inflammatory bowel disease; PG, pyoderma gangrenosum; TNF, tumor 
necrosis factor  
 
